Pharma giants in 2023: Breaking down revenue streams by leading product categories

Image from https://torange.biz/medications-big-money-19928

The pharma sector saw robust revenues across several key therapeutic areas in the second quarter of 2023, with oncology, immunology, and infectious diseases leading the pack. Merck’s blockbuster cancer drug Keytruda maintained its oncology dominance with sales topping $6 billion, while AbbVie’s Humira regained its crown as the world’s best-selling drug despite new competition. Gilead’s HIV regimen Biktarvy and Merck’s human papillomavirus vaccine Gardasil also posted strong growth. Additionally, neurology emerged as an area of expansion for companies like Roche, AbbVie and Biogen.

Our breakdown of 2023 pharma revenue by product categories, based on an analysis of Q2 data from 15 Big Pharma companies, reveals that oncology led the way with revenues surpassing $52 billion. Following closely was immunology with over $23 bil…

Read more
  • 0

PsychoGenics’ SmartCube prompts a reevaluation of CNS drug discovery

SmartCube integrates behavioral neurobiology, robotics and computer vision to process and analyze large temporal and vector-based datasets. This platform uses proprietary bioinformatics and probabilistic causal inference algorithms to explore compounds’ potential to treat psychiatric disorders. [Image courtesy of PsychoGenics]

In an era of rapid AI progress, the quest to pioneer the first AI-developed drug candidates has led to an increasing number of these drug candidates entering clinical trials. One contender is ulotaront, an antipsychotic drug, that fared well in a phase 3 schizophrenia study published in NEJM in 2020. The trace amine-associated receptor 1 agonist has entered phase 2/3 studies to test its potential in generalized anxiety disorder and as an adjunctive therapy for major depressive disorder treatment.

“Not only is this the first drug discovered using machine learning that’s th…

Read more
  • 0